Market Cap 238.90M
Revenue (ttm) 0.00
Net Income (ttm) -30.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,412,300
Avg Vol 3,138,304
Day's Range N/A - N/A
Shares Out 125.08M
Stochastic %K 22%
Beta 2.62
Analysts Strong Sell
Price Target $6.83

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 200 5278
Address:
7 Times Square, Suite 2503, New York, United States
Volkajikk1
Volkajikk1 Oct. 25 at 4:18 PM
$SLS 🙄
0 · Reply
Volkajikk1
Volkajikk1 Oct. 25 at 4:16 PM
$SLS how did that Friday AH PR go? 😂
0 · Reply
rpc630
rpc630 Oct. 25 at 4:11 PM
0 · Reply
D541
D541 Oct. 25 at 4:06 PM
$SLS https://hedgefollow.com/stocks/SLS
0 · Reply
OnTheBalance
OnTheBalance Oct. 25 at 4:01 PM
$SLS Calling up all you investors who like doing valuations. IMMUNE ENHANCING (Non Toxic) therapies that increase overall survival not by months, but by YEARS changes the input data significantly, might say turns it all upside down and on its head. Big Dog BPs and their product planning bean counters get it. It's not all clear yet as to how much greater the revenue potentials are. So first, lets say AML CR2 patients start living 2 years or 3 years longer. The numbers entering the CR2 phase each year remain unchanged, but the patient pool (GPS) will keep growing each year, as the numbers dying on the exit end drops substantially. Now move that therapy to AML CR1 patient.. they start remaining in remission years longer, so that pool (also GPS) starts to expand to huge numbers, but maybe the flow to CR2 starts to reduce. Now bring on SLS009.. maybe to FRONT LINE.. and again one starts to upset all the math on the pools of CR2 and CR1. and that's just AML. Next, Apply this to other cancers.
1 · Reply
New_to_stock
New_to_stock Oct. 25 at 3:56 PM
$SLS If you want to make money buy $2 PUTS at open Monday morning.
1 · Reply
Juhanialainen
Juhanialainen Oct. 25 at 3:48 PM
$SLS Would you take $50 in January, or $236 in July after the frontline study?
1 · Reply
jacksparo
jacksparo Oct. 25 at 3:46 PM
$SLS $LAES $GEVO $BTBT $AKBA The next two weeks might be the most important in 2025 for these stocks … There will updates about LAES and BTBT in my Sunday VIP team email tomorrow ✅📈🏅✅📈🏅! Enjoy the rest of your weekend 📈📈📈!
1 · Reply
takeshoot
takeshoot Oct. 25 at 3:40 PM
$SLS ouch 😉
2 · Reply
PeterRaslow
PeterRaslow Oct. 25 at 3:38 PM
$SLS I don't think this POS will move past $4.X ,look at $SNDX they will not pay out the call contracts,
0 · Reply
Latest News on SLS
Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

Aug 19, 2025, 9:18 PM EDT - 2 months ago

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026


SELLAS Announces Key Business Objectives for 2025

Jan 8, 2025, 8:20 AM EST - 10 months ago

SELLAS Announces Key Business Objectives for 2025


SELLAS Life Sciences Announces Proposed Public Offering

Jan 3, 2024, 8:05 PM EST - 1 year ago

SELLAS Life Sciences Announces Proposed Public Offering


Volkajikk1
Volkajikk1 Oct. 25 at 4:18 PM
$SLS 🙄
0 · Reply
Volkajikk1
Volkajikk1 Oct. 25 at 4:16 PM
$SLS how did that Friday AH PR go? 😂
0 · Reply
rpc630
rpc630 Oct. 25 at 4:11 PM
0 · Reply
D541
D541 Oct. 25 at 4:06 PM
$SLS https://hedgefollow.com/stocks/SLS
0 · Reply
OnTheBalance
OnTheBalance Oct. 25 at 4:01 PM
$SLS Calling up all you investors who like doing valuations. IMMUNE ENHANCING (Non Toxic) therapies that increase overall survival not by months, but by YEARS changes the input data significantly, might say turns it all upside down and on its head. Big Dog BPs and their product planning bean counters get it. It's not all clear yet as to how much greater the revenue potentials are. So first, lets say AML CR2 patients start living 2 years or 3 years longer. The numbers entering the CR2 phase each year remain unchanged, but the patient pool (GPS) will keep growing each year, as the numbers dying on the exit end drops substantially. Now move that therapy to AML CR1 patient.. they start remaining in remission years longer, so that pool (also GPS) starts to expand to huge numbers, but maybe the flow to CR2 starts to reduce. Now bring on SLS009.. maybe to FRONT LINE.. and again one starts to upset all the math on the pools of CR2 and CR1. and that's just AML. Next, Apply this to other cancers.
1 · Reply
New_to_stock
New_to_stock Oct. 25 at 3:56 PM
$SLS If you want to make money buy $2 PUTS at open Monday morning.
1 · Reply
Juhanialainen
Juhanialainen Oct. 25 at 3:48 PM
$SLS Would you take $50 in January, or $236 in July after the frontline study?
1 · Reply
jacksparo
jacksparo Oct. 25 at 3:46 PM
$SLS $LAES $GEVO $BTBT $AKBA The next two weeks might be the most important in 2025 for these stocks … There will updates about LAES and BTBT in my Sunday VIP team email tomorrow ✅📈🏅✅📈🏅! Enjoy the rest of your weekend 📈📈📈!
1 · Reply
takeshoot
takeshoot Oct. 25 at 3:40 PM
$SLS ouch 😉
2 · Reply
PeterRaslow
PeterRaslow Oct. 25 at 3:38 PM
$SLS I don't think this POS will move past $4.X ,look at $SNDX they will not pay out the call contracts,
0 · Reply
Nelvestor
Nelvestor Oct. 25 at 3:33 PM
$SLS shall we talk BO figures after we've seen topline... we don't even know if the HR comes in under 0.636 yet
2 · Reply
samsha1
samsha1 Oct. 25 at 3:26 PM
$SLS Just like us retail, Big Pharma is waiting for the next Keytruda. Define targets like WT1 and ASXL1m, proven OS benefit, low toxicity, and ad infinitum dosing across adult + pediatric settings… Look no further. 🚀
0 · Reply
canowhupass
canowhupass Oct. 25 at 3:23 PM
$SLS the following thread is context for historical price gaps after PH3 top line release: What caused the sharp increase in share price for ABVX in July of this year? The sharp increase in Abivax SA (NASDAQ: ABVX) share price in July 2025 was primarily triggered by the company’s announcement of positive top-line results from two Phase 3 clinical trials of its lead drug candidate, obefazimod, for the treatment of moderate to severe ulcerative colitis (UC). The data, released after market close on July 22, 2025, showed that obefazimod met its primary endpoint of clinical remission in both trials, marking a significant milestone for the oral therapy as a potential first-in-class treatment. This news led to a dramatic single-day surge of over 580% in ABVX shares on July 23, 2025, with the stock opening in premarket trading up more than 400% before closing sharply higher. The rally was fueled by analyst upgrades and enthusiasm from biotech investors, who viewed the results as de-risking
3 · Reply
D541
D541 Oct. 25 at 3:00 PM
$SLS events forecast for the 28th /29th I'll be in 2 days conference/ meetings so I won't be able to be on the screen all the time , when do you guys think some news could drop?new
3 · Reply
samsha1
samsha1 Oct. 25 at 2:16 PM
$SLS limited indications, but the TAM blows you away. So the $20 B BO is the floor. We have not touched 20-40 other indications.
7 · Reply
vlucky16
vlucky16 Oct. 25 at 2:09 PM
$SLS I like Dogs, big, or small especially the under dogs in a big game. I would love to be Serge in his position. Is he the big dog or the little dog? Big dog pharma has ran into another Big Dog SLS.
0 · Reply
OnTheBalance
OnTheBalance Oct. 25 at 1:48 PM
$SLS There is bound to be some stress among the Big Dogs whose existing revenue streams may be interrupted if Precision Immunology treatments (non toxic) gain rapid acceptance in certain quarters (MSKCC, MD Anderson, FDA etc). But then the high level of competitiveness among the Big Dogs might prove very beneficial to the Small Dog busy developing these innovations and therapies over past many years. Which Big Dog wants to win the most and is speedy enough to gain the prize?
0 · Reply
Heypentaco
Heypentaco Oct. 25 at 1:21 PM
$SLS Who in their right mind would pay to put out articles giving this a $7 price target? What hedge fund. They don't say who did on the actual pieces saying this. $ 7 ? $ 7 . Really? These people aren't Boy Scouts. I'll take what is behind the last curtain way at the end, thank you and FYPM.
2 · Reply
Barbaro69
Barbaro69 Oct. 25 at 1:02 PM
$SLS https://youtu.be/tqw5ykoDF7U?si=sYUlXhykkiehbNGO
1 · Reply
Rogerrabbit
Rogerrabbit Oct. 25 at 12:47 PM
$SLS Have a nice weekend longs and take good care of your dogs 😎🏖💪👊🐕 Playful & Hopeful: “Gotta love dogs—big or small—and keep smiling… big things are coming in biotech!” Cheerful & Professional: “From little breakthroughs to big leaps—keep smiling! Exciting biotech news ahead 🧬🐾” Mystery & Optimism: “Can’t share the details yet, but let’s just say biotech’s about to get even more amazing. Keep smiling—and keep loving dogs, big or small!” Short & Catchy: “Smiles, science, and surprises ahead in biotech 🧬🐶 Stay tuned!”
1 · Reply
Marcus737
Marcus737 Oct. 25 at 12:43 PM
$SLS Submitted my question. Do all patients who reach Cr/Cri and don't have a reduction in WT1 (log3?) be treated with GPS if Regal is successful? Cr1/sct.
1 · Reply
TheDenniSystem
TheDenniSystem Oct. 25 at 12:32 PM
$SLS Okay I’ll spell it out for us again: he’s saying the big dawgs ie big pharma are currently loving the little dawgs which is us! It’s a very simple riddle which implies the BO process has begun! Or Or he’s found a girl he’s falling for, and she happens to love dogs. It’s clearly one or the other!
1 · Reply